












7th International PacRim Breast and Prostate Cancer Meeting
17-20 March 2019, Barossa Valley, South Australia
Program





Platinum Sponsor

| Sunday, March 17 | |
|------------------|--|
| 11:00 - 1:00 | Registration and Poster Set-up |
| 1:00 - 1:15 | Welcome – Wayne Tilley (DRMCRL, Adelaide) and Elgene Lim (Garvan Inst, Sydney) |
| 1:15 - 1:30 | “Breast and prostate cancer - more similar than different” Theresa Hickey (DRMCRL, Adelaide) and Luke Selth (DRMCRL, Adelaide) |
| 1:30 - 3:00 |  Session I: Thousands of genomes – now what? Co-Chairs: Vanessa Hayes (Garvan Inst, Sydney), Ed Gelmann (Columbia Uni, New York) |
| | 1. Janet Stanford (Fred Hutch, Seattle); <i>Genetic susceptibility and risk stratification for prostate cancer screening and prevention</i> |
| | 2. Oscar Rueda (CRUK, Cambridge); <i>Statistical approaches to personalised medicine in breast cancer</i> |
| | 3. Felix Feng (UCSF, San Francisco); <i>Basal vs luminal molecular subtyping in breast and prostate cancer: Implications for treatment selection</i> |
| | 4. Adrian Lee (UPMC, Pittsburgh); <i>Overcoming inter-patient heterogeneity – intra-patient analysis of breast cancer evolution</i> |
| | General Discussion (40-45 mins) |
| 3:00 - 3:20 | Coffee Break |
| 3:20 – 4:50 |  Session II: Estrogen & Androgen receptors: still key drivers? Co-Chairs: Gail Risbridger (Monash Uni, Melbourne), Elgene Lim (Garvan Inst, Sydney) |
| | 1. Steffi Oesterreich (Uni of Pittsburgh, Pittsburgh); <i>Estrogen receptor alterations - the most frequent cause of death from breast cancer?</i> |
| | 2. Ganesh Raj (UT Southwestern, Dallas); <i>Overcoming endocrine resistance: masterminds, metaphors and mutants</i> |
| | 3. Theresa Hickey (DRMCRL, Adelaide); <i>When is AR oncogenic in breast cancer?</i> |
| | 4. Steve Balk (Beth Israel DMC, Boston); <i>Persistent AR activity in enzalutamide resistant prostate cancer</i> |
| | 5. Geof Greene (Uni of Chicago, Chicago); <i>Unexpected therapeutic efficacy of a SERM in mutant ER breast cancer</i> |
| | General Discussion (40-45 mins) |
| 5:00 – 5:55 |  Flash Talks Co-Chairs: Renea Taylor (Monash Uni, Melbourne), Colleen Nelson (Translational Research Inst / QUT, Brisbane) |
| 6:00 - 6:45 |  “Ron Ross Award” presentation – Funmi Olopade, MD (University of Chicago) Co-Chairs: Wayne Tilley (DRMCRL, Adelaide), Elgene Lim (Garvan Inst, Sydney) |
| 7:15 - 11:00 | Welcome Reception - Novotel |
| Monday, March 18 | |
| 7:00 - 8:30 | Breakfast |
| 8:30 - 10:00 |  Session III: Endocrine Resistance – common mechanisms? Co-Chairs: David Waugh (TRI/QUT, Brisbane); Suzanne Fuqua (Baylor College of Medicine, Houston) |
| | 1. Rinath Jeselsohn (Dana-Farber Inst, Boston); <i>Endocrine resistance: The most common clinical mechanism</i> |
| | 2. Luca Magnani (Imperial College London, London); <i>Endocrine resistance – common mechanisms? Not really. To each its own, a single cell tale of resistance</i> |
| | 3. Scott Dehm (Uni of Minnesota, Minneapolis); <i>Endocrine uncoupling: When androgen receptors are no longer receptors</i> |
| | 4. Manav Korpai (H3 Biomedicine Inc, Cambridge, USA); <i>Discovery and development of a first-in-class oral selective ERα covalent antagonist (SERCA) for the treatment of ERα^{WT/MUTb} breast cancer</i> |
| | General Discussion (40-45 mins) |
| 10:00 - 10:30 | Break |

| | |
|---|--|
| 10:30 - 12:00  | Session IV: Other 'omics Co-Chairs: Gail Prins (Uni of Illinois, Chicago), Chris Ormandy (Garvan Inst, Sydney) |
| | 1. Housheng Hansen He (Uni of Toronto, Toronto); <i>Transcriptomic and functional landscape of circular RNA in prostate and breast cancer</i> |
| | 2. Gavin Ha (Fred Hutch, Seattle); <i>Profiling whole cancer genomes from circulating tumor DNA</i> |
| | 3. Wilbert Zwart (Netherlands Cancer Inst, Amsterdam); <i>Cistromics in clinical trials: Mechanistic insights in tumorigenesis and disease progression</i> |
| | 4. Alex Swarbrick (Garvan Institute, Sydney); <i>Multi-dimensional single cell analysis of the tumour microenvironment</i> |
| | General Discussion (40-45 mins) |
| 12:00 - 1:10 | Lunch |
| 1:10 - 2:40  | Session V: Cell plasticity and tumorigenesis Co-Chairs: Judith Clements (QUT, Brisbane), Greg Goodall (Centre for Cancer Biology, Adelaide) |
| | 1. Leigh Ellis (Dana-Farber Cancer Inst, Boston); <i>Targeting lineage plasticity in RB1 deficient cancer</i> |
| | 2. Amina Zoubeidi (Uni of BC, Vancouver); <i>Cell plasticity in treatment-resistant prostate cancer</i> |
| | 3. Natasha Kyprianou (Uni of Kentucky, Lexington); <i>Overcoming prostate cancer resistance by phenotypic reprogramming</i> |
| | 4. Jane Visvader (WEHI, Melbourne); <i>Dissecting intraclonal plasticity during breast oncogenesis</i> |
| | General Discussion (40-45 mins) |
| 2:40 - 3:00 | BioScientifica Presentation |
| 3:00 - 3:20 | Break |
| 3:20 - 4:50  | Session VI: Harnessing the immune system Co-Chairs: Mike Brown (Royal Adelaide Hospital, Adelaide), Anthony Joshua (Garvan Inst, Sydney) |
| | 1. Shahneen Sandhu (PeterMac, Melbourne); <i>Immunotherapy in prostate cancer: challenges and progress</i> |
| | 2. Anita Dunbier (Uni of Otago, Dunedin); <i>Immune involvement and therapies in ER-positive breast cancer</i> |
| | 3. Belinda Parker (LaTrobe Uni, Melbourne); <i>Reversing tumour invisibility in bone to combat metastatic disease</i> |
| | 4. David Quinn (USC, Los Angeles); <i>Role of tumor blood vessels and response to check point inhibitors</i> |
| | 5. Carlo Palmieri (Uni of Liverpool, Liverpool); <i>Immunotherapy for breast cancer: challenges and opportunities</i> |
| | General Discussion (40-45 mins) |
| 7.00 - 11:00  | <i>Dinner - Chateau Tanunda (Buses depart Novotel from 5.45pm)</i> |
| Tuesday, March 19 | |
| 7:00 - 8:30 | Breakfast |
| 8:30 - 10:00  | Session VII: Novel therapeutic targets Co-Chairs: Chris Sweeney (Dana-Farber Cancer Inst, Boston), Carlo Palmieri (Uni of Liverpool, Liverpool) |
| | 1. Charlotte Bevan (Imperial College, London); <i>MicroRNAs: a potential new therapeutic avenue</i> |
| | 2. Andrei Goga (UCSF, San Francisco); <i>New metabolic and mitotic targets in TNBC</i> |
| | 3. Simak Ali (Imperial College, London); <i>Therapeutic targeting of gene regulatory processes in breast cancer</i> |
| | 4. Geoff Lindeman (WEHI, Melbourne); <i>Targeting cell survival pathways in breast cancer using BH3 mimetics</i> |
| | General Discussion (40-45 mins) |
| 10:00 - 10:30 | Break |

| | |
|--|--|
| <p>10:30 - 12:00</p>  | <p>Session VIII: New instruments in the breast and prostate cancer symphony Co-Chairs: Eva Corey (UWash, Seattle), Stephen Birrell (Uni of Adelaide, Adelaide)</p> |
| | <p>1. David Gallego-Ortega (Garvan Institute, Sydney); <i>A novel biomimetic tissue engineering platform to understand molecular mechanisms of drug resistance at single cell resolution</i></p> |
| | <p>2. Richard Iggo (Uni of Bordeaux, Bordeaux); <i>What I cannot create, I do not understand: are MIND models the answer?</i></p> |
| | <p>3. Violeta Serra (Vall d'Hebron Institute of Oncology, Barcelona); <i>Challenges and opportunities using ER-positive patient-derived tumour xenograft models</i></p> |
| | <p>4. Dietmar Hutmacher (QUT, Brisbane); <i>Convergence of regenerative medicine principles to develop new breast and prostate cancer mice models</i></p> |
| | <p>General Discussion (40-45 mins)</p> |
| <p>12:00 - 1:00</p> | <p>Lunch</p> |
| <p>1:00 - 4:30</p> | <p>Free time</p> |
| <p>4:30 - 6:30</p>  | <p>Poster Session with winetasting by Jo Irvine  <i>Lévrier</i> is a James Halliday top 10 new winery in 2019</p> |
| <p>7:00 – 11:00</p> | <p>Dinner - Novotel</p> |
| <p>8:15 - 9:30</p>  | <p>The Great Debate – “Are humans the only model?” Moderator: Chris Sweeney For: Alex Swarbrick, <i>Team Captain</i> Melissa Davis, Scott Dehm, Luca Magnani, Steffi Oesterreich, Amina Zoubeidi Against: Carol Lange, <i>Team Captain</i> Charlotte Bevan, Steve Birrell, Donald McDonnell, Sam Oakes, Wilbert Zwart Judges: Suzanne Fuqua, Geof Greene, Gail Prins, Gail Risbridger (plus one from each Team)</p> |
| <p>Wednesday, March 20</p> | |
| <p>7:00 - 8:30</p> | <p>Breakfast</p> |
| <p>8:30 - 10:00</p>  | <p>Session IX: Nuclear receptors & Co-Regulators: What's new? Co-Chairs: Carol Lange (Uni of Minnesota, Minneapolis), Robert Matusik (Vanderbilt University, Nashville)</p> |
| | <p>1. Jason Carroll (CRUK, Cambridge, UK); <i>How many associated proteins? What ones are important?</i></p> |
| | <p>2. Frank Claessens (KU Leuven Uni, Leuven); <i>Live from an androgen receptor lab: some old news revisited</i></p> |
| | <p>3. Carol Sartorius (Uni of Colorado, Denver); <i>PR-RAR crosstalk in breast cancer</i></p> |
| | <p>4. Richard Pestell (Baruch S. Blumberg Inst, Philadelphia); <i>DACH1 gene deletion extends portraits of human prostate cancer</i></p> |
| | <p>5. Patricia Elizalde (Inst de Biología y Medicina Experimental, Buenos Aires); <i>My name is ErbB-2, I will be called a transcription factor</i></p> |
| | <p>General Discussion (40-45 mins)</p> |
| <p>10:00 – 10:30</p> | <p>Break</p> |
| <p>10:30 – 12:00</p>  | <p>Session X: Cellular homeostasis Co-Chairs: Jeff Holst (Uni of NSW, Sydney), Sam Oakes (Garvan Inst, Sydney)</p> |
| | <p>1. Ian Mills (Oxford Uni, Oxford); <i>Contributions of the unfolded protein response and glycosylation to homeostasis</i></p> |
| | <p>2. David Thomas (Broad Inst, Boston); <i>Aggressive cancer homeostasis through dynamic flux</i></p> |
| | <p>3. Lisa Butler (Uni of Adelaide/SAHMRI, Adelaide); <i>Membrane lipid remodelling: untapped opportunities to predict and disrupt metastasis of hormone-dependent cancers.</i></p> |
| | <p>4. Vincent Giguère (McGill Uni, Montreal); <i>The AR/mTOR/DNA-PK nuclear complexes: the missing links in prostate cancer?</i></p> |
| | <p>5. Donald McDonnell (Duke Uni, Durham); <i>Dyslipidemia and breast cancer pathobiology</i></p> |
| | <p>General Discussion (40-45 mins)</p> |
| <p>12:00 - 1:15</p> | <p>Lunch</p> |

| | |
|---|---|
| 1:15 - 2:45 | Session XI: Building a rabbit proof fence: the tumour “terroir” Co-Chairs: Elizabeth Williams (QUT, Brisbane), Robin Anderson (ONJCRI, Melbourne) |
|  | 1. Leonie Young (RCSI, Dublin); <i>Understanding the transcriptomic circulatory – blocking the rabbit holes early</i> |
| | 2. Pete Nelson (Fred Hutch, Seattle); <i>Intrinsic and extrinsic drivers of micro- and macro-metastasis</i> |
| | 3. Jason Lee (QIMR Berghofer, Brisbane); <i>Harnessing the epigenome: a handbrake for metastasis</i> |
| | 4. Christine Chaffer (Garvan Inst, Sydney); <i>Cancer cell plasticity drives the development of chemoresistance in breast cancer</i> |
| | General Discussion (40-45 mins) |
| 2:45 - 3:00 | Break |
| 3.00 - 4.30 | Inaugural “Rob Sutherland Award” Co-Chairs: David Quinn (USC, Los Angeles), Lisa Horvath (Chris O’Brien LifeHouse, Sydney) |
| | TBA: Presenters to be selected from eligible candidates based on submitted abstract and CV |
| 4.30 | Meeting Close |
| 7:00 - 11:00 |  <i>Big Bash Conference Dinner - Seppeltsfield (Buses depart Novotel from 5.45pm)</i> |
| Thursday, March 21 | |
| 7:00 - 9:00 | Breakfast & Check out |
| Approx. 9.30 | Bus to airport /city |
| | |